Is Egrifta (Tesamorelin) Legal in Missouri?
HealthRX.com
Egrifta is FDA-approved, but this page covers federal rules only
Key numbers
- 5%Share of tesamorelin patients whose HbA1c reached 6.5% or higher by week 26, versus 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 25%Share of tesamorelin patients with injection-site reactions in the first 26 weeks, versus 14% in the comparison groupSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 2 mgVial strength of Egrifta SV, one of the two current tesamorelin formulationsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Tesamorelin
At a glance
- Drug / Tesamorelin, sold as Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial) [2][3]
- FDA approval / Egrifta first approved November 10, 2010, application BLA 022505 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Approved dose / Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily; not substitutable [2][3]
- Compounding lists / In no category of FDA's bulk-substance lists for state-licensed pharmacies or outsourcing facilities [4][5][6]
- Sport / Prohibited at all times under WADA section S2.2.4 [7]
What the FDA approval covers
FDA approved tesamorelin on November 10, 2010 under application BLA 022505; the application began as an NDA and was deemed a BLA on March 23, 2020 [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026, and both once-daily subcutaneous injections [2][3].
The approved use is narrow: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label states that long-term cardiovascular safety has not been established, and that the drug is not indicated for weight loss because its effect on weight is neutral [2].
Doses differ between the two products. Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) into the abdomen once daily; Egrifta WR is 1.28 mg (0.16 mL) once daily. The labels state that the two are not substitutable [2][3]. Tesamorelin is a growth hormone-releasing factor analog, not growth hormone: it stimulates pituitary GRF receptors so the pituitary releases the body's own growth hormone, which raises IGF-1 [2].
Compounding status
Tesamorelin is absent from FDA's list of bulk substances that may present significant safety risks when compounded (dated April 22, 2026) and from every category of FDA's bulk-substance list for state-licensed pharmacies and physicians (updated May 14, 2026) and for outsourcing facilities (updated March 21, 2025) [4][5][6]. FDA has made no category-based statement about compounding it [4][5][6]. It is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [8][9]. Absence from those lists is not approval: a compounded drug is not FDA-approved, and FDA does not review a compound's safety, effectiveness or quality before it is marketed [8][9].
Questions worth asking
Athletes: prohibited at all times
WADA names tesamorelin in section S2.2.4, among growth hormone-releasing factors, GHRH and its analogues [7]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [7]. It is on the 2026 List and remains on the 2027 List [7][10].
What the label says to watch for
Tesamorelin is contraindicated in disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or the excipients, and pregnancy [2][3]. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated 52 weeks, 34% and 23% [2]. HbA1c of 6.5% or higher developed in 5% versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [2]. Injection-site reactions occurred in 25% versus 14% during the first 26 weeks [2].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is Egrifta (tesamorelin) legal in Missouri?
Can a compounding pharmacy make tesamorelin?
Is tesamorelin approved for weight loss?
Is tesamorelin banned in sport?
What dose do the labels give?
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Official web page.
- Official web page.
- World Anti-Doping Agency.